Article Information
vol. 7 no. 4
Published By
Online ISSN
History
- Received July 14, 2021
- Accepted September 9, 2021
- Published online December 6, 2021.
Article Versions
- previous version (September 24, 2021 - 06:51).
- You are viewing the most recent version of this article.
Copyright & Usage
Copyright ©The authors 2021 This version is distributed under the terms of the Creative Commons Attribution Licence 4.0.
Author Information
- Stephen G. Noorduyn1,2⇑,
- Karissa Johnston3,4,
- Kathy Osenenko3,
- Niroshan Sriskandarajah1,
- Alain Gendron5 and
- Lawrence Mbuagbaw2
- 1AstraZeneca Canada Ltd, Mississauga, ON, Canada
- 2Dept of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada
- 3Broadstreet HEOR, Vancouver, BC, Canada
- 4Memorial University, St John's, NL, Canada
- 5Dept of Medicine, University of Montreal, Montreal, QC, Canada
- Stephen G. Noorduyn (stephen.noorduyn{at}astrazeneca.com)
Funding
AstraZeneca Canada
Article usage
Altmetrics
Vol 7 Issue 4
Table of Contents
Discontinuation of benralizumab in Canadian patients with severe eosinophilic asthma
